HAL blue-light cystoscopy in high-risk nonmuscle-invasive bladder cancer-Re-TURBT recurrence rates in a prospective, randomized study

Urology

Volumn 76, Issue 3, 2010, Pages 664-669

  Geavlete, Bogdan ^a   Jecu, Marian ^a   Multescu, Razvan ^a   Georgescu, Dragos ^a   Geavlete, Petrisor ^a  

^a Saint John Emergency Clinical Hospital   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER; MITOMYCIN C; 5-AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID; CARBON;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; BLUE LIGHT; CANCER INVASION; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TRANSURETHRAL RESECTION; URINE CYTOLOGY; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DIAGNOSTIC USE; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR; SCINTISCANNING; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARBON RADIOISOTOPES; CYSTOSCOPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 78549267752     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.02.067     Document Type: Article

References (30)

1. B. Geavlete, R. Multescu, and D. Georgescu Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder noninvasive bladder tumors J Endourol 23 6 2009 977 981
2. C.R. Riedl, D. Daniltchenko, F. Koenig, R. Simak, S.A. Loening, and H. Pflueger Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer J Urol 165 2001 1121 1123
3. M. Babjuk, W. Oosterlinck, and R. Sylvester Guidelines on TaT1 (Non-Muscle Invasive) Bladder Cancer edition:1-19. 2009 European Association of Urology Guidelines
4. K. Thomas, and T. O'Brien Blue-sky thinking about blue-light cystoscopy BJU Int 104 2009 887 890
5. L. Schips, H. Augustin, and R.E. Zigeuner Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59 2 2002 220 223
6. H.W. Herr The value of a second transurethral resection in evaluating patients with bladder tumors J Urol 162 1999 74 76
7. A. Mersdorf, A. Brauers, and J.M. Wolff Second transurethral resection for superficial bladder cancer: a must? J Urol 159 Suppl 1998 143
8. T.A. Vogeli, M. Grimm, and R. Ackermann Prospective study for quality control of transurethral resection of bladder tumors by routine second transurethral resection J Urol 159 Suppl 1998 143
9. T. Filbeck, U. Pichlmeier, and R. Knuechel Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors J Urol 168 1 2002 67 71
10. M. Miladi, M. Peyromaure, and M. Zerbib The value of transurethral resection in evaluating patients with bladder tumors Eur Urol 43 2003 241 245
11. Grossman HBimproving the management of bladder cancer with fluorescence cystoscopy J Environ Pathol Toxicol Oncol 26 2 2007 143 147
12. A. Marti, P. Jichlinski, and N. Lange Comparison of aminolevulinic acid and Hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer J Urol 170 2003 428 432
13. P. Jichlinski, L. Guillou, and S.J. Karlsen Hexyl aminolevulinate fluorescence cystoscopy: A new diagnostic tool for the photodiagnosis of superficial bladder cancerA multicenter study J Urol 170 2003 226 229
14. Y. Fradet, H.B. Grossman, and L. Gomella A comparison of Hexaminolevulinate fluorescence cystoscopy and White light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: A phase III, multicenter study J Urol 178 2007 68 73 (Pubitemid 46908730)
15. W. Loidl, J. Schmidbauer, and M. Susani Flexible cystoscopy assisted by Hexaminolevulinate induced fluorescence: A new approach for bladder cancer detection and surveillance? Eur Urol 47 2005 323 326
16. J. Schmidbauer, F. Witjes, and N. Schmeller Improved detection of urothelial carcinoma in situ with Hexaminolevulinate fluorescence cystoscopy J Urol 171 2004 135 138
17. Z. Kirkali, T. Chan, and M. Manoharan Bladder cancer: epidemiology, staging and grading, and diagnosis Urology 66 2005 4 34
18. M. Brausi, L. Collette, and K. Kurth Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
19. M.O. Grimm, C. Steinhoff, and X. Simon Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study J Urol 170 2003 433 437
20. T. Divrik, U. Yildirim, and A. Eroglu Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 175 4 2006 1258 1261
21. D.I. Daniltchenko, C.R. Riedl, and M.D. Sachs Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study J Urol 174 6 2005 2129 2133
22. S. Denzinger, M. Burger, and B. Walter Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study Urology 69 4 2007 675 679
23. M. Schulze, N. Stotz, and J. Rassweiler Retrospective analysis of transurethral resection, second-look resection, and long-term Chemo-Metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach J Endourol 21 12 2007 1533 1541
24. H.E. Schwaibold, S. Sivalingam, and F. May The value of a second transurethral resection for T1 bladder cancer BJU Int 97 6 2006 1199 1201
25. M.A. Zurkirchen, T. Sulser, and A. Gaspert Second transurethral resection of superficial transitional cell carcinoma of the bladder: a must even for experienced urologists Urol Int 72 2 2004 99 102
26. S. Holmang, and S.L. Johansson Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression J Urol 167 4 2002 1634 1637
27. P. Alken, M. Siegsmund, K. Gromoll-Bergmann, P. Daffner, W. Fenner, and J.W. Spelz A randomised controlled multicentre trial to compare the efects of transurethral detection and resection of bladder carcinomas under 5-ALA induced fluorescence light to conventional white light Eur Urol Suppl 6 2 2007 171
28. A.S. Stenzl, W.R. Roessler, Y.F. Fradet, L.M. Mynderse, M.S. Soloway, M.K. Kriegmair, F.W. Witjes, and H.B.G. Grossman Hexvix. ® fluorescence cystoscopy improves detection and resection of papilary bladder cancer and reduces early recurence: A multicentre, prospective, randomized study Eur Urol Suppl 6 2 2007 171
29. M.A. Brausi Arguments against the use of fluorescence for the diagnosis of nonmuscle-invasive bladder tumours (NMIBT) Eur Urol Supplements 7 2008 430 433
30. J.A. Witjes Fluorescence cystoscopy in bladder cancer: the Case Pro Eur Urol Supplements 7 2008 426 429